CN114929217A - 基于ampk抑制功能和锌稳态控制功能用于治疗多发性硬化的药物组合物 - Google Patents

基于ampk抑制功能和锌稳态控制功能用于治疗多发性硬化的药物组合物 Download PDF

Info

Publication number
CN114929217A
CN114929217A CN202080093043.2A CN202080093043A CN114929217A CN 114929217 A CN114929217 A CN 114929217A CN 202080093043 A CN202080093043 A CN 202080093043A CN 114929217 A CN114929217 A CN 114929217A
Authority
CN
China
Prior art keywords
indol
thiazol
amino
methylene
ylmethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093043.2A
Other languages
English (en)
Chinese (zh)
Inventor
金良姬
严在源
徐相源
崔普永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zinc Medical Corp
Original Assignee
Zinc Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zinc Medical Corp filed Critical Zinc Medical Corp
Publication of CN114929217A publication Critical patent/CN114929217A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080093043.2A 2019-11-14 2020-11-12 基于ampk抑制功能和锌稳态控制功能用于治疗多发性硬化的药物组合物 Pending CN114929217A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190145709 2019-11-14
KR10-2019-0145709 2019-11-14
PCT/KR2020/015932 WO2021096270A1 (ko) 2019-11-14 2020-11-12 Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
CN114929217A true CN114929217A (zh) 2022-08-19

Family

ID=75911395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093043.2A Pending CN114929217A (zh) 2019-11-14 2020-11-12 基于ampk抑制功能和锌稳态控制功能用于治疗多发性硬化的药物组合物

Country Status (6)

Country Link
US (1) US12343335B2 (https=)
EP (1) EP4066832A4 (https=)
JP (1) JP7398840B2 (https=)
KR (1) KR102770734B1 (https=)
CN (1) CN114929217A (https=)
WO (1) WO2021096270A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255419A (en) * 1979-09-27 1981-03-10 Allergan Pharmaceuticals, Inc. Zinc deficiency in multiple sclerosis
US20120172333A1 (en) * 2009-09-10 2012-07-05 Glaxosmithkline Llc Pyrrolo-pyridine derivatives as activators of ampk
CN103533934A (zh) * 2011-03-17 2014-01-22 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
US20190167647A1 (en) * 2016-08-09 2019-06-06 Industry Academy Cooperation Foundation Of Sejong University Pharmaceutical composition for stroke treatment based on ampk inhibition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241020A1 (en) 2002-08-29 2006-10-26 Applied Research Systems Ars Holdings N.V. Protein tyrosine phosphatase inhibitors
KR101324647B1 (ko) 2010-12-10 2013-11-01 한국과학기술연구원 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255419A (en) * 1979-09-27 1981-03-10 Allergan Pharmaceuticals, Inc. Zinc deficiency in multiple sclerosis
US20120172333A1 (en) * 2009-09-10 2012-07-05 Glaxosmithkline Llc Pyrrolo-pyridine derivatives as activators of ampk
CN103533934A (zh) * 2011-03-17 2014-01-22 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
US20190167647A1 (en) * 2016-08-09 2019-06-06 Industry Academy Cooperation Foundation Of Sejong University Pharmaceutical composition for stroke treatment based on ampk inhibition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BO YOUNG CHOI: "Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model", 《NEUROBIOLOGY OF DISEASE》, vol. 54, 27 January 2013 (2013-01-27), XP028580806, DOI: 10.1016/j.nbd.2013.01.012 *
BO YOUNG CHOI: "The Emerging Role of Zinc in the Pathogenesis of Multiple Sclerosis", 《INT. J. MOL. SCI》, vol. 18, no. 10, 28 September 2017 (2017-09-28), pages 1 - 11 *
刘 芳: "地高辛原位杂交显示锌转运体3mRNA 在脑、脊髓和脊神经节中的分布", 《CHINESE JOURNAL OF ANATOMY》, vol. 31, no. 62008, 25 December 2008 (2008-12-25), pages 747 - 750 *
尚晓玲;张家颖;公培刚;刘爱东;陆培信;胡亚男;: "益肾达络饮对实验性自身免疫性脑脊髓炎小鼠CREB、P-CREB表达的影响", 中国老年学杂志, no. 23, 10 December 2015 (2015-12-10) *

Also Published As

Publication number Publication date
US12343335B2 (en) 2025-07-01
US20230000839A1 (en) 2023-01-05
KR102770734B1 (ko) 2025-02-21
JP2023501814A (ja) 2023-01-19
JP7398840B2 (ja) 2023-12-15
EP4066832A1 (en) 2022-10-05
KR20220088750A (ko) 2022-06-28
WO2021096270A1 (ko) 2021-05-20
EP4066832A4 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
US11517572B2 (en) Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid
Ou et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice
Stackman et al. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment
Inden et al. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson’s disease rat model
Royea et al. Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease
Feng et al. Therapeutic effect of modulating TREM-1 via anti-inflammation and autophagy in Parkinson’s disease
Wang et al. Honokiol ameliorates amyloidosis and neuroinflammation and improves cognitive impairment in Alzheimer’s disease transgenic mice
US20170312253A1 (en) Methods of preventing and treating cerebral amyloid angiopathy (caa) with an edaravone medicament
Li et al. HDAC3 inhibitor (BRD3308) modulates microglial pyroptosis and neuroinflammation through PPARγ/NLRP3/GSDMD to improve neurological function after intraventricular hemorrhage in mice
US20160310481A1 (en) Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
Wang et al. Protective effects of ACY-1215 against chemotherapy-related cognitive impairment and brain damage in mice
CN109073634A (zh) 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
Li et al. Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice
Shin et al. Scutellarin ameliorates learning and memory deficit via suppressing β-amyloid formation and microglial activation in rats with chronic cerebral hypoperfusion
Chen et al. The role of the GRP78/PERK/ATF4 pathway in the ability of Gua Lou Gui Zhi decoction to attenuate apoptosis by inhibiting endoplasmic reticulum stress after ischemia-reperfusion injury
Upīte et al. Subchronic administration of auranofin reduced amyloid-β plaque pathology in a transgenic APPNL-GF/NL-GF mouse model
Wang et al. CZ-7, a new derivative of Claulansine F, promotes remyelination induced by cuprizone by enhancing myelin debris clearance
CN103547289A (zh) 治疗阿尔茨海默氏病的方法和组合物
TWI798552B (zh) 用於治療腦發炎和損傷並改善功能恢復的小窩蛋白１抗體
Koros et al. Effects of AraC treatment on motor coordination and cerebellar cytoarchitecture in the adult rat: A possible protective role of NAC
KR102770734B1 (ko) Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물
CN113750236A (zh) 一种vegfr抑制剂在制备抗阿尔兹海默症药物中的应用
KR20160060137A (ko) Ampk 활성화 화합물 및 이의 용도
Hossain et al. KIT-13, a novel plasmalogen derivative, attenuates neuroinflammation and amplifies cognition
Yang et al. Carboxyaminotriazole: A bone savior in collagen-induced arthritis—Halting osteoclastogenesis via interleukin-1β downregulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220819